Datramol

Form: tablets
Dosage: Tramadol hydrochloride 37.5 mg & Paracetamol 325 mg
Packaging: 10 orodispersible tablets

Active substance: tramadol – paracetamol
Form: orodispersible tablet with mint odour
Dosage per tablet: Tramadol hydrochloride 37.5 mg & Paracetamol 325 mg
Packaging: Box of 10 orodispersible tablets
Target: adults and children over 12 years

Datramol® orodispersible tablets are indicated for the symptomatic treatment of moderate to severe pain, in adults and adolescents (12 years and older).

Adults and adolescents (12 years and older)

The dose should be individually adjusted according to intensity of pain and response of the patient. Normally, the lowest effective dose with analgesic effect should be selected.
An initial dose of two tablets of Datramol® is recommended.

Additional doses can be taken as needed, not exceeding 8 tablets (equivalent to 300 mg tramadol and 2600 mg paracetamol) per day.
The dosing interval should not be less than six hours.

It is generally not necessary to adjust the dose in patients under the age of 75 years without clinically significant hepatic or renal impairment.
Datramol should not be administered for longer than is strictly necessary.

Prescription drugs. Please contact your doctor.

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma